Patented Omega-3 Technology enables Physician Recommended Nutriceuticals to offer a powerful and proven method for producing healthy tears

PLYMOUTH MEETING, Pa., Sept. 7, 2016 /PRNewswire/ -- The U.S. Patent and Trademark Office issued PRN Physician Recommended Nutriceuticals a method patent for their omega-3 nutriceutical formulation, providing further evidence that PRN's unique and scientific omega-3 formation provides the exact nutrition for the creation of healthy tears therefore alleviating occasional dry eye symptoms. This is the second patent awarded to PRN in less than a year on its PRN Dry Eye Omega Benefits^® nutriceutical product.

PRN's method patent improves outcomes for patients suffering from occasional dry eye symptoms by enabling the body to better absorb nutrition essential for healthy vision maintenance. This represents a monumental achievement for PRN as method patents are very difficult to come by in the under-regulated nutriceutical space. This method patent demonstrates both the scientific rigor of PRN's approach and its foundation in method-based research. 

"This is an exciting time for PRN. The issuance of this second patent further strengthens our intellectual property and provides a true differentiator in the market place," said Ken Krieg, CEO of PRN Physician Recommended Nutriceuticals.

This now protected technology improves and enhances the lipid layer of the tear film and increases tear break-up time by elevating the omega-3 index in patients suffering from occasional dry eye symptoms, meibomian gland dysfunction and other eye concerns.

When there is an imbalance in the ratio of healthy fats, the meibum becomes inflamed and the oil composition thickens. This can result in blockage of the meibomian glands. The blockage of these glands prevents the production of the important tear film lipid layer. Without this layer, the aqueous layer evaporates leaving a tear that is irritating to the eye.   

PRN's patented formulation provides omega-3s in a purified triglyceride form. Research shows that omega-3s in this form provide essential nutrition for the ocular surface as well as help maintain healthy vision.  This patented formula delivers a total amount of 2668 mg of omega-3s in re-esterified triglyceride form (rTG), which provides up to three times better absorption by the body than other over-the-counter forms.

"PRN is committed to putting clinical data and scientific evidence behind our products," said Dr. Michael Gross, Senior Vice President and Chief Medical Officer, PRN Physician Recommended Nutriceuticals. "This method patent provides measurable systemic results and gives our partners the confidence to recommend our unique omega-3 nutriceuticals to their patients."

About PRN Physician Recommended Nutriceuticals

PRN is a leading producer of omega-3 nutriceuticals.  Developed by doctors and recommended by world-renowned medical thought leaders, PRN's products are supported by medical evidence and offer exceptional quality and purity.  PRN is one of the fastest growing privately held companies and has appeared on the INC 5000 list for 4 years in a row.

Logo - http://photos.prnewswire.com/prnh/20160902/403861LOGO

SOURCE PRN Physician Recommended Nutriceuticals

Related Links

http://www.prnomegahealth.com